pocketful logo light
pocketful logo light
Concord Biotech Ltd logo

Concord Biotech Ltd

NSE: CONCORDBIO BSE: 543960

₹1051.20

(4.40%)

Mon, 01 Jun 2026, 06:01 pm

mtf coin illustrationMTF 5x

Concord Biotech Share Price Live Chart

1 Day

(4.40%)

No Result Found

Summary

  • Market Cap

    10972.67

  • Net Profit

    371.64

  • P/B

    9.67

  • Sector P/E

    33.76

  • P/E

    47.19

  • EV/EBITDA

    31.89

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    14.04

  • RONW (Industry)

    13.17

  • ROE

    22.26

  • ROCE

    29.53

  • Debt/Equity

    0

  • EPS (TTM)

    30.10

  • Dividend Yield

    0.83

  • Book Value

    174.68

  • Interest Cover

    476.53

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters44.0844.0844.0844.0844.08
FII7.807.588.039.119.35
DII9.229.589.558.879.16
Public38.9038.7638.3337.9537.41
Government00000

Read More

Technical Analysis

RSI

40.63

MACD

-6.25

50 DMA

1094.61

200 DMA

1343.28

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1496.371302.471176.831108.57982.93914.67720.77
Fibonacci1302.471228.401182.641108.571034.50988.74914.67
Camarilla1104.521086.751068.971108.571033.431015.65997.88

Pivots Level: Classic

R3

+387.80

1496.37

R2

+193.90

1302.47

R1

+68.27

1176.83

1108.57
1108.57
Pivot Point
LTP: 1061.30

S1

-125.63

982.93

S2

-193.90

914.67

S3

-387.80

720.77

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1106.18

  • 20-EMA

    1115.90

  • 30-EMA

    1116.70

  • 50-EMA

    1125.09

  • 100-EMA

    1182.91

  • 200-EMA

    1312.98

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
29 May 2026board-meetingsAccounts, Final Dividend
11 Feb 2026board-meetingsQuarterly Results
13 Nov 2025board-meetingsQuarterly Results
13 Aug 2025agm
03 Aug 2025dividendFinal Dividend - Rs. - 10.703 Sept 2025
29 May 2025dividend₹10.70 Dividend /Share03 Sept 2025
23 May 2024agm
23 May 2024dividend₹8.75 Dividend /Share22 Jun 2024
22 May 2024dividendDividend - Rs. - 8.7522 Jun 2024
21 May 2024agmAnnual General Meeting23 Jun 2024

Read More

Peer Comparison

Concord Biotech Ltd logo

Concord Biotech Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Concord Biotech Ltd About

Concord Biotech is engaged in research and development manufacturing, marketing and selling of pharmaceutical products. The Company’s API manufacturing facilities are located at Dholka and Limbasi, and its formulations facility at Valthera in the state of Gujarat, India.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1984

Headquarters

CEO

SUDHIR JAIRAM VAID

Employees

Contact

Website icon

Website

http://www.concordbiotech.com

Email icon

Email

complianceofficer@concordbiotech.com

Phone icon

Phone

91-079-68138700

Location icon

Location

1482-86 Trasad Road, Dholka, Ahmedabad, Gujarat, 382225

Read More

Concord Biotech Ltd Company History

YearHistory
2018
  • The Company underwent its fifth USFDA inspection and received a 'no action indicated' classification for the facility located at Dholka.
  • The Company received a GMP certification from the Food and Drugs Control Administration for the Valthera and Dholka units.
  • The Company underwent its second USFDA inspection at the Valthera facility and received an establishment inspection report.
  • The Company established a Joint Venture in Japan.
2019
  • The Company received two ANDA approvals.
  • The Company expanded its business in the critical care segment in India.
  • The Company commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg.
2020
  • The Board permitted the layout plan for the proposed injectable manufacturing unit at the Valthera facility.
  • The Company received two ANDA approvals.
  • The Company made its first shipment of Mycophenolate Sodium Tablets to the US market.
2021
  • The Company commenced operations at the second API facility at Limbasi.
  • The Company underwent its third EU GMP inspection of the manufacturing facility located in Dholka.
2023
  • The Company completed the USFDA inspection at the Limbasi facility.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
NK SECURITIES RESEARCH PRIVATE LIMITEDbulkBuy6169521217.9425 Feb 2026
NK SECURITIES RESEARCH PRIVATE LIMITEDbulkSell6169521218.5825 Feb 2026
UBS PRINCIPAL CAPITAL ASIA LIMITEDbulkSell7401592589.8620 Sept 2024
THE VANGUARD GROUP INC A/C VANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VANGUARD INTERNATbulkBuy5771832596.0820 Sept 2024
THE VANGUARD GROUP INC A/C VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUNDbulkBuy6979362596.0820 Sept 2024
NORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBALbulkBuy6000001386.9528 May 2024
1575773 ONTARIO INCbulkSell35482111361.2628 May 2024
BNP PARIBAS ARBITRAGEblockSell1534211421.725 Jan 2024
SOCIETE GENERALEblockBuy1534211421.725 Jan 2024
GRAVITON RESEARCH CAPITAL LLPbulkBuy735455935.1718 Aug 2023

Read More

Concord Biotech Ltd News

Concord Biotech Optimistic on Strong FY27 Growth

Concord Biotech remains optimistic about strong growth in FY27, driven by product expansion and customer diversification strategies.

30 May 2026

companies

Concord Biotech board meets May 29

Concord Biotech board meets on May 29, 2026 to consider Q4FY26 audited results. The meeting will also consider recommending a final dividend.

23 May 2026

companies

Citi Cuts Concord Biotech Target Price to ₹1,190

Citi maintains Neutral rating on Concord Biotech but slashes target price from ₹1,680 to ₹1,190, citing 20-23% EPS cuts for FY26-27 amid API slowdown and margin compression.

20 Apr 2026

investment-ideas

Concord Biotech Block Trade Worth Rs. 31.11 Crores

Concord Biotech Ltd. witnessed a significant NSE block trade involving 290,728 shares valued at Rs. 31.11 crores, executed at Rs. 1070.00 per share, indicating institutional interest in the pharmaceutical company.

10 Apr 2026

equity-markets

Concord Biotech Files Q4FY26 Compliance Certificate

Concord Biotech submitted mandatory quarterly certificate under SEBI regulations, confirming no dematerialization requests received during Q4FY26 period ended March 31, 2026.

08 Apr 2026

companies

Read More